PubMed:32178765 / 2546-2739 JSONTXT

Annnotations TAB JSON ListView MergeView

Inflammaging

Id Subject Object Predicate Lexical cue
T17 0-193 Sentence denotes Serious adverse events up to week 24 occurred in no patients receiving guselkumab every 4 weeks, four (3%) patients receiving guselkumab every 8 weeks, and five (4%) patients receiving placebo.
T17 0-193 Sentence denotes Serious adverse events up to week 24 occurred in no patients receiving guselkumab every 4 weeks, four (3%) patients receiving guselkumab every 8 weeks, and five (4%) patients receiving placebo.

yaoziqian_800_3

Id Subject Object Predicate Lexical cue
T17 71-81 CI denotes guselkumab
T18 126-136 CI denotes guselkumab
T19 185-192 CI denotes placebo

Zierdiyeerkenaili_800_3

Id Subject Object Predicate Lexical cue
T15 71-81 CI denotes guselkumab
T16 126-136 CI denotes guselkumab
T24 185-192 CI denotes placebo